Nama's AI scorecard currently rates Tarsus Pharmaceuticals Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does TARS report earnings?

Tarsus Pharmaceuticals's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$4.82.

What is the TARS price target?

The median analyst price target from 9 analysts is $100.00, with a range of $88.00 – $116.00.

Is TARS Shariah compliant?

Nama's AAOIFI-style screen reads Tarsus Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Tarsus Pharmaceuticals (TARS)

Healthcare · Biotechnology · NASDAQ

Tarsus Pharmaceuticals (TARS) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.38B and a free-cash-flow yield of -0.8%. Over the most recent reported fiscal year, revenue grew 146.7%. Nama's AI scorecard rates it Hold, 4.5 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Hold · 4.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Middle · +8.1% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-25.1%

How far the last close sits under the highest price of the past five years.

Market cap	$3.38B
Trailing P/E	—
Price / book	8.6
Price / sales	5.3
FCF yield	-0.8%
Dividend yield	—
Gross margin	93.3%
Operating margin	-8.0%
Net margin	-7.7%
Revenue growth (YoY)	+146.7%
Revenue growth (3-yr annual)	+159.5%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.5
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

TARS earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate -$4.82). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	-$0.87	-$1.77	+50.9%	$194.57M
Q2 2026	Aug 6, 2026	-$0.43	-$0.20	-115.0%	$173.91M
Q1 2026	May 6, 2026	-$0.16	-$0.42	+61.9%	$162.05M
Q4 2025	Feb 23, 2026	-$0.20	$0.01	-2100.0%	$151.67M

TARS analyst price target

Median target $100.00 from 9 analysts, ranging $88.00 – $116.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live TARS data on Nama Insights →

TARS FAQ

Is TARS a buy?: Nama's AI scorecard currently rates Tarsus Pharmaceuticals Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does TARS report earnings?: Tarsus Pharmaceuticals's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$4.82.
What is the TARS price target?: The median analyst price target from 9 analysts is $100.00, with a range of $88.00 – $116.00.
Is TARS Shariah compliant?: Nama's AAOIFI-style screen reads Tarsus Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.